InspireMD公司近日宣布，美国食品药品监督管理局（FDA）已正式批准其针对Switchguard神经保护系统开展的Cguardians III关键性研究的器械豁免申请。这一重要监管里程碑为该创新医疗器械的临床研究铺平了道路。
InspireMD公司近日宣布，美国食品药品监督管理局（FDA）已正式批准其针对Switchguard神经保护系统开展的Cguardians III关键性研究的器械豁免申请。这一重要监管里程碑为该创新医疗器械的临床研究铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.